10-QPeriod: Q3 FY2014

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2014

Filed November 10, 2014For Securities:MRK

Summary

Merck & Co., Inc. reported sales of $10.6 billion for the third quarter of 2014, a 4% decrease year-over-year, impacted by foreign exchange headwinds and lower sales across several key products including Victrelis, Gardasil, and Temodar. Despite the sales decline, the company demonstrated strong operational performance, with net income attributable to Merck & Co., Inc. of $895 million, leading to diluted earnings per share of $0.31. This performance was significantly boosted by notable strategic transactions, including the sale of its Consumer Care business to Bayer for $14.2 billion, which is expected to generate a substantial pretax gain, and the acquisition of Idenix Pharmaceuticals for approximately $3.9 billion to strengthen its focus on viral diseases, particularly Hepatitis C. The company continues to navigate a challenging market environment characterized by healthcare cost containment and pricing pressures. However, proactive portfolio management, exemplified by the strategic divestitures and acquisitions, alongside ongoing restructuring efforts aimed at improving efficiency, position Merck to adapt to these challenges. Investors should note the significant one-time events influencing the quarter's results, which may require careful consideration when evaluating the company's underlying operational trends.

Financial Highlights

52 data points
Beta

Revenue

$10.56B

60.0% Gross Margin

Net Income

$895.00M

8.5% Net Margin

EPS (Diluted)

$0.31

Total Assets

$101.81B

Cash & Equivalents

$11.37B

Free Cash Flow

$4.35B

Financial Statements
Beta
Revenue$10.56B
Cost of Revenue$4.22B
Gross Profit$6.33B
R&D Expenses$1.66B
SG&A Expenses$2.98B
Interest Expense$191.00M
Net Income$895.00M
EPS (Basic)$0.31
EPS (Diluted)$0.31
Shares Outstanding (Basic)2.88B
Shares Outstanding (Diluted)2.91B

Key Highlights

  • 1Third quarter 2014 sales were $10.6 billion, a 4% decrease year-over-year, driven by lower sales of key products and divestitures.
  • 2Net income attributable to Merck & Co., Inc. was $895 million, resulting in diluted EPS of $0.31.
  • 3Completed the sale of the Consumer Care business to Bayer for $14.2 billion, expected to yield a significant pretax gain.
  • 4Acquired Idenix Pharmaceuticals for approximately $3.9 billion, bolstering the pipeline in viral disease treatments, especially Hepatitis C.
  • 5Restructuring programs are ongoing, with substantial cost savings anticipated by the end of 2015, aimed at enhancing efficiency.
  • 6Continued investment in research and development, with Keytruda (pembrolizumab) receiving FDA approval for melanoma, marking a significant advancement in oncology.

Frequently Asked Questions

Merck's sales in the third quarter of 2014 were $10.6 billion, a 4% decrease compared to the prior year. This decline was primarily attributed to lower sales of key products such as Victrelis, Gardasil, Temodar, Singulair, and Cozaar/Hyzaar. Additionally, the divestiture of certain products and the termination of the AstraZeneca LP relationship also contributed to the revenue decrease. These factors were partially offset by growth in the diabetes franchise (Januvia/Janumet), Implanon/Nexplanon, Simponi, Dulera, and the Animal Health business.

Merck completed two major strategic transactions. First, they sold their Consumer Care business to Bayer AG for $14.2 billion, which is expected to result in a significant pretax gain. Second, Merck acquired Idenix Pharmaceuticals for approximately $3.9 billion to enhance its focus on viral diseases, particularly Hepatitis C, by integrating Idenix's pipeline, including MK-3682.

Merck is actively pursuing restructuring programs, including the 2013 Restructuring Program and the ongoing Merger Restructuring Program. These initiatives are designed to streamline operations, reduce the workforce, and improve efficiency. The company anticipates substantial annual net cost savings of approximately $2.5 billion by the end of 2015 from these combined efforts, which is expected to positively impact future financial performance.

The diabetes franchise, particularly Januvia/Janumet, showed positive growth in Q3 2014, with combined sales increasing 5% year-over-year. Looking ahead, Merck received FDA approval for Keytruda (pembrolizumab) for melanoma, a significant advancement in their oncology portfolio. They are also advancing other promising candidates in areas like HCV, Alzheimer's, and osteoporosis, indicating a robust R&D pipeline that could drive future growth.